

PROXY/VOTING BY CORRESPONDENCE FORM

The Annual General Meeting of Scandion Oncology A/S ("Scandion Oncology" or the "Company") on May 26, 2021, at 3.00 PM (CET)
 at the Company's address Fruebjergvej 3, DK-2100 Copenhagen Ø, Denmark

Name of shareholder: _____
 Address: _____
 Zip code and city: _____

I, the Undersigned hereby grant authority by proxy or vote by correspondence at the Annual General Meeting of Scandion Oncology A/S to be held on **May 26, 2021** as set out below:

Please mark the appropriate box A), B), C), or D). Please note that it is only possible either to grant authority by proxy or to vote by correspondence.

A) Proxy is given to an identified third person:

 Name and address of the proxy holder (CAPITAL LETTERS)

B) Proxy is given to the Board of Directors (with a right to substitution) to vote in accordance with the recommendations of the Board of Directors as stated in the table below.

C) Proxy is given to the Board of Directors (with a right of substitution) to vote in accordance with the voting directions given below. Please mark the box "FOR", "AGAINST" or "ABSTAIN" to indicate your directions.

D) The vote by correspondence is given in accordance with the voting directions given below. Please mark the box "FOR", "AGAINST" or "ABSTAIN" to indicate your directions. The vote by correspondence is irrevocable.

Items on the agenda (the full agenda is included in the notice of the meeting)	FOR	AGAINST	ABSTAIN	The Board's recommendation
1. Election of chairman of the meeting	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	FOR*
3. Presentation of the audited Annual Report 2020 for approval	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
4. Discharge for the Board of directors and the executive management	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
5. Decision regarding use of surplus or coverage of losses according to the approved Annual Report 2020	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
6. Election of auditor	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	FOR*
7. Proposal regarding authorization to increase the Company's share capital	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
8. Proposal regarding authorization to issue of warrants and any related capital increase	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
9. Proposal regarding amendment of terms for existing warrants the Company's CEO and employees	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
10. Proposal to amend article 6.4 of the Company's articles of association by including decision on discharge	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
11. Proposal to amend article 9.1 of the Company's articles of association regarding the size of the Board of Directors	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR

12. Election of members to the Board of Directors A) Re-election of Peter Høngaard Andersen B) Re-election of Jørgen Bardenfleth C) Re-election of Carl Borrebaeck D) Re-election of Bo Rode Hansen E) Re-election of Thomas Feldthus F) Re-election of Christian Vinding Thomsen G) Election of Martin Møller	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	FOR* FOR* FOR* FOR* FOR* FOR* FOR*
13. Proposal to amend the Company's articles of association as a consequence of the Company's listing on Nasdaq First North Growth Market	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
14. Approval of new board fees	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR

*In connection with the election of persons (election of chairman of the meeting (item 1), auditor (item 5) and members of the board of directors (item 11), votes may only be cast in favour of the proposed candidates or in favour of alternative candidates proposed for the positions in question. Consequently, the proxy form cannot be used to vote against the proposed candidates.

A form that has only been dated and signed shall be considered as a proxy given to the Board of Directors to vote in accordance with the recommendations of the Board of Directors as they appear in the table above.

The proxy shall apply to all subjects discussed at the Annual General Meeting. If new proposals are presented and put to the vote, including proposals for amendments, the proxy holder shall vote on your behalf in accordance with his or her own convictions. The proxy/vote by correspondence applies to the number of shares in the possession of the undersigned on the record date, May 19, 2021. The shareholding is calculated on the basis of the entry in the Company's register of shareholders and notifications on ownership that the Company has received, but not yet entered in the register of shareholders.

This power of attorney shall be sent to CFO Carit Jacques Andersen, e-mail: cja@scandiononcology.com, so that it has arrived no later than May 25, 2021 at 10.00 AM (CET).

					2	0	2	1
--	--	--	--	--	---	---	---	---

Signature